Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

NEW YORK, December 30, 2025, 15:29 ET — Regular session

  • Progressive shares rose about 0.7% to $230 in afternoon trade.
  • A regulatory filing showed director Charles A. Davis donated 87,755 shares to a charitable foundation.
  • U.S. stocks were little changed in holiday-thin trading, while insurance peers edged modestly higher.

Shares of The Progressive Corporation (NYSE:PGR) were up about 0.7% at $230 on Tuesday afternoon after a regulatory filing disclosed a large gift of stock by a company director. The stock traded between $227.53 and $230.03, with about 1.0 million shares changing hands.

The disclosure lands in a year-end market where liquidity is thin and small shifts in positioning can show up quickly in defensive financials such as insurers.

Progressive is also heading into a key stretch for the personal auto insurance group, where investors tend to focus on whether premium pricing is keeping pace with claims costs, and how management describes the outlook for 2026.

A Form 4 filing with the U.S. Securities and Exchange Commission showed director Charles A. Davis donated 87,755 common shares on Dec. 23. The filing reported Davis held 250,222 shares after the transaction. 1

Form 4 is the SEC’s standard disclosure for insider transactions and other ownership changes by directors and officers. Davis’ filing listed the transfer as a gift at $0 per share, rather than an open-market sale.

Progressive’s move came alongside a muted rise in the insurance group. The State Street SPDR S&P Insurance ETF was up about 0.1%, while Allstate and Travelers also edged higher.

More broadly, U.S. stocks were choppy and close to flat in holiday-thin trade as investors digested minutes from the Federal Reserve’s December meeting, Reuters reported. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. 2

Insurers are sensitive to rate expectations because they invest premiums in bonds; shifts in yields can influence investment income over time. For auto-focused carriers, the bigger swing factor is whether repairs, medical costs and used-car pricing pressure claims severity.

Progressive’s investor calendar lists its “December earnings release” for Jan. 28, 2026, the next scheduled company update. 3

Investors typically pay close attention to underwriting margins and policy growth in that release. A key metric is the combined ratio — the share of premium dollars consumed by claims and expenses; a ratio below 100 means underwriting profit.

Progressive shares have traded in a 52-week range of roughly $199.90 to $292.99, according to MarketWatch, leaving the stock well below its peak even after Tuesday’s gain. 4

For now, the combination of a narrow day-to-day tape and the approach of late-January results is likely to keep focus on any incremental read-through on pricing, loss-cost trends and the broader path for U.S. rates.

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus
Previous Story

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears
Next Story

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Go toTop